Entero MedTech tops 15% of revenue as expansion advances

Entero Healthcare Solutions Limited said its MedTech business made up more than 15% of total revenue in H1 FY27, and management identified the larger MedTech mix as one of three drivers of Q2 FY27 gross-margin expansion of 126 basis points to 11.5%.

How large is Entero's MedTech business in H1 FY27?

Entero said MedTech represented more than 15% of total revenue in H1 FY27, but did not disclose the segment's exact revenue, profit or earnings before interest, tax, depreciation and amortisation, or EBITDA, margin. The company reported consolidated H1 FY27 revenue of Rs 4,028 crore, up 35% year on year, establishing MedTech as a material part of the group mix without a precise divisional rupee figure.

Management said it had not provided a segment margin because cost allocations would be required across different businesses. The disclosed 15%-plus share therefore does not permit a calculation of MedTech revenue or profitability from H1 FY27 revenue of Rs 4,028 crore. It does show that the category was large enough for management to cite its growing contribution to the group’s profitability.

Entero’s distribution base gives MedTech access to more than 2,900 hospital customers and over 92,200 retail customers served in H1 FY27. The company distributed more than 90,400 stock-keeping units, or SKUs, sourced from over 3,200 healthcare-product manufacturers across about 500 districts in more than 20 states and union territories. Management’s plan is to use this existing customer and supplier network to broaden its healthcare-products offering.

Why did Entero link MedTech to margin expansion?

Entero said the growing MedTech revenue share was one of three drivers of Q2 FY27 gross-margin expansion of 126 basis points year on year to 11.5%. The other two stated drivers were scale-led procurement economies and the deliberate exit from certain low-margin accounts. Q2 FY27 EBITDA margin rose 135 basis points to 5.3%, while EBITDA increased 78% year on year.

Management did not say that all MedTech products earn more margin than pharmaceutical distribution. It said margins depend on the value added to a transaction: plain-vanilla MedTech distribution may resemble pharma distribution, whereas demand-generation work can generate higher margins. Management said the same distinction applies to pharma products where Entero provides demand-generation services.

An analyst asked whether MedTech margin was above the company’s blended margin, but management did not provide a numerical answer. Entero reported an 11.5% gross margin in both Q2 FY27 and H1 FY27, while its H1 FY27 EBITDA margin was 5.2%. The evidence supports management’s view that a larger MedTech mix aided group margin expansion, not a conclusion that the entire category has a single uniform margin.

Management also said potential revisions to maximum retail prices, or MRPs, and trade-margin caps were not likely to affect its overall margin structure. It said distributors were not receiving the bulk of the gap between MRP and manufacturers’ selling prices, with much of that gap accruing to final customers such as hospitals. That assessment was made against Entero’s Q2 FY27 consolidated gross margin of 11.5%, which covers all businesses rather than MedTech alone.

How does Entero plan to grow its MedTech categories?

Entero plans to expand MedTech organically through new product categories, deeper penetration in existing markets and stronger partnerships with medical-technology manufacturers. The company said these initiatives can use its H1 FY27 footprint of about 500 districts and more than 2,900 hospital customers. The strategy is portfolio expansion and additional services alongside pharmaceutical distribution, rather than building a separate distribution network.

Management said MedTech distribution shares several features with pharmaceutical distribution, including fragmented markets, the importance of manufacturer relationships and the need for efficient market access. It sees scope for portfolio expansion, value-added services and an improved margin profile. Its operating mechanism is to offer more product categories and services through a network that handled more than 90,400 SKUs in H1 FY27.

Acquisitions may supplement organic growth, although Entero completed no acquisitions in H1 FY27. Management said it was evaluating opportunities that could expand its portfolio, add product categories it does not currently handle or improve its presence in new geographies. When asked about priorities, management said it was generally more interested in product expansion.

Entero said it was no longer evaluating very small acquisitions because of its current scale. Management noted that historic acquisitions had ranged from Rs 20 crore to Rs 400 crore, while giving no target value for current opportunities. It said some opportunities under evaluation could close in FY27, but did not identify a MedTech transaction or provide a timetable.

What does MedTech mean for Entero's FY27 outlook?

Entero said it was in a comfortable position to deliver better than its previous FY27 guidance of about 23% consolidated revenue growth, excluding contributions from new acquisitions. The previous guidance also included a 5% EBITDA margin and conversion of 50% of EBITDA into operating cash flow. Management did not issue a revised numerical target for MedTech revenue, margins or category additions.

The group’s H1 FY27 revenue grew 35% year on year to Rs 4,028 crore, while Q2 FY27 revenue increased 32.9% to Rs 2,087 crore. On a like-for-like basis, Q2 growth was 34.7% after adjusting for revenue recognised on a net-margin basis and a subsidiary divestment in the base period. Organic growth was 18.2%, or 20% on the like-for-like basis, while calendarisation of prior-year acquisitions added 14.7%.

Management said the calendarisation benefit from acquisitions completed in the previous year would taper partly in Q3 FY27 and more in Q4 FY27 unless new acquisitions are announced. This makes expansion in existing categories, including MedTech, relevant to sustaining growth after the acquisition contribution declines. There were no acquisitions in the first half of FY27.

H1 FY27 operating cash flow was negative Rs 46.5 crore, affected by delayed government-contract collections after funds were reallocated because of drought conditions in Maharashtra. Net working-capital days were 66 in H1 FY27, compared with 68 in the comparable prior-year period. Management said its 50% EBITDA-to-operating-cash-flow conversion guidance remained unchanged.

Conclusion

Entero’s disclosure places MedTech at more than 15% of H1 FY27 revenue within a Rs 4,028 crore healthcare-distribution platform. The category is central to the company’s mix strategy because management included it among the reasons for Q2 FY27 gross-margin expansion to 11.5%, while making clear that value-added services, not product labels alone, determine transaction margins.

The next measures are progress in new category additions, penetration of existing markets and partnerships with medical-technology manufacturers, alongside any acquisition announcement. Management said it is evaluating product and geographic opportunities and expects FY27 performance to exceed its earlier guidance of about 23% revenue growth and 5% EBITDA margin, but it has not set a separate MedTech sales or profitability target.